Company intelligence / Profile preview

Suzhou Ruiming New Drug Research & Development

Suzhou, Jiangsu Sheng, Chinacrunchbase.com ↗

Ownership: Private
Development stage: Other

Overview

Suzhou Ruiming New Drug Research & Development is a Chinese biotech/pharma company focused on developing chemical drugs for ophthalmic indications. Its lead asset, RMP-A03, has completed Phase 2 clinical trials for pterygium. Another candidate, RA1115-B1, has completed Phase 1 studies in healthy volunteers as an eye drop formulation. No published results or efficacy data are available from these trials.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

RMP-A03

1 more asset in the full pipeline.

Request access →

Partnerships

Gloria Ying (strategic cooperation announced)

Beyond the preview

Go deeper on Suzhou Ruiming New Drug Research & Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Ruiming New Drug Research & Development.

Explore the full profile